Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $36.20, but opened at $38.22. Ascentage Pharma Group International shares last traded at $37.05, with a volume of 4,017 shares.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. initiated coverage on shares of Ascentage Pharma Group International in a report on Thursday, March 27th. They set an "overweight" rating on the stock.
Read Our Latest Research Report on Ascentage Pharma Group International
Ascentage Pharma Group International Trading Up 1.9%
The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 3.24. The business has a fifty day moving average of $32.24.
Hedge Funds Weigh In On Ascentage Pharma Group International
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC bought a new stake in Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned 0.18% of Ascentage Pharma Group International at the end of the most recent reporting period.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Recommended Stories
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
